HYPERTENSION IN THE ELDERLY A BALANCED APPROACH. Barry Goldlist October 31, 2014

Similar documents
DISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.

Objectives. Describe results and implications of recent landmark hypertension trials

Hypertension Update Clinical Controversies Regarding Age and Race

Managing Hypertension in 2016

HYPERTENSION GUIDELINES WHERE ARE WE IN 2014

We are delighted to have Dr. Roetzheim with us today to discuss Managing Hypertension in Older Adult Patients.

JNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH

Modern Management of Hypertension

Management of Lipid Disorders and Hypertension: Implications of the New Guidelines

HYPERTENSION MANAGEMENT IN ELDERLY POPULATIONS

MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk

Preventing and Treating High Blood Pressure

Hypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute

ADVANCES IN MANAGEMENT OF HYPERTENSION

Modern Management of Hypertension: Where Do We Draw the Line?

Hypertension in the Elderly. John Puxty Division of Geriatrics Center for Studies in Aging and Health, Providence Care

MANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION

4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?

Pre-ALLHAT Drug Use. Diuretics. ß-Blockers. ACE Inhibitors. CCBs. Year. % of Treated Patients on Medication. CCBs. Beta Blockers.

New Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.

ALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial

JNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults

Update in Hypertension

Hypertension Pharmacotherapy: A Practical Approach

Hypertension Management Controversies in the Elderly Patient

Difficult to Treat Hypertension

Hypertension Management: A Moving Target

Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital

Hypertension Update. Objectives 4/28/2015. Beverly J. Mathis, D.O. OOA May 2015

Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension

Hypertension 2015: Recent Evidence that Will Change Your Practice

New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets

Disclosures. Learning Objectives. Hypertension: a sprint to the finish Ontario Pharmacists Association 1

First line treatment of primary hypertension

7/7/ CHD/MI LVH and LV dysfunction Dysrrhythmias Stroke PVD Renal insufficiency and failure Retinopathy. Normal <120 Prehypertension

ADVANCES IN MANAGEMENT OF HYPERTENSION

Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM

Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures

Treating Hypertension in 2018: What Makes the Most Sense Today?

State of the art treatment of hypertension: established and new drugs. Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland

DISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE

Prevention of Heart Failure: What s New with Hypertension

Younger adults with a family history of premature artherosclerotic disease should have their cardiovascular risk factors measured.

Int. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 06, Pages: JNC 8 versus JNC 7 Understanding the Evidences

Cedars Sinai Diabetes. Michael A. Weber

Hypertension Update 2016 AREEF ISHANI, MD MS CHIEF OF MEDICINE MINNEAPOLIS VA MEDICAL CENTER PROFESSOR OF MEDICINE UNIVERSITY OF MINNESOTA

Jared Moore, MD, FACP

Treating Hypertension in Individuals with Diabetes

Combination Therapy for Hypertension

Antihypertensive Trial Design ALLHAT

Hypertension Update Warwick Jaffe Interventional Cardiologist Ascot Hospital

The JNC 8 Guidelines: A Clinical Review

In the Literature 1001 BP of 1.1 mm Hg). The trial was stopped early based on prespecified stopping rules because of a significant difference in cardi

APPENDIX D: PHARMACOTYHERAPY EVIDENCE

By Prof. Khaled El-Rabat

STANDARD treatment algorithm mmHg

Blood Pressure Targets: Where are We Now?

Hypertension Update. Mayo Clinic 90 th Annual Clinical Reviews November 2 nd and 16 th, 2016

Evolving Concepts on Hypertension: Implications of Three Guidelines (JNC 8 Panel, ESH/ESC, NICE/BSH)

Combination therapy Giuseppe M.C. Rosano, MD, PhD, MSc, FESC, FHFA St George s Hospitals NHS Trust University of London

Disclosures. Hypertension: Nationwide Dilemma. Learning Objectives. What s Currently Recommended? Specific Concerns 3/9/2012

Hypertension in the elderly

Hypertension: What s new since JNC 7. Harold M. Szerlip, MD, FACP, FCCP, FASN, FNKF

Hypertension diagnosis (see detail document) Diabetic. Target less than 130/80mmHg

Hypertension and the SPRINT Trial: Is Lower Better

New Hypertension Guidelines: Why the change? Neil Brummond, M.D. Avera Medical Group Internal Medicine Sioux Falls, SD

Dr Narender Goel MD (Internal Medicine and Nephrology) Financial Disclosure: None, Conflict of Interest: None

, 13TH EUGMS CONGRESS NICE GOALS OF ANTIHYPERTENSIVE TREATMENT IN THE FRAIL IS SPRINT APPLICABLE? CONTRA

Implementation of JNC- 8 Hypertension Recommendations: Combining evidence and value-based practice strategies for accountable care

ALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic

T. Suithichaiyakul Cardiomed Chula

Management of Hypertension in Women

Managing Hypertension in 2018

Dr. Khan Abul Kalam Azad Associate Professor Department of Medicine SZRMC, Bogra

Hypertension. Most important public health problem in developed countries

ALLHAT. ALLHAT Antihypertensive Trial Results by Baseline Diabetic & Fasting Glucose Status

Hypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic

Blood Pressure LIMBO How Low To Go?

Hypertension targets in the elderly. Sarah McCracken Consultant Geriatrician North Bristol NHS Trust September 2016

Hypertension CHAPTER-I CARDIOVASCULAR SYSTEM. Dr. K T NAIK Pharm.D Associate Professor Department of Pharm.D Krishna Teja Pharmacy College, Tirupati

Primary hypertension in adults

Don t let the pressure get to you:

So what do patients think about hypertension? This systematic review of the literature raised some important points (BMJ 2012;345:e3953):

Hypertension in the very old. Objectives: Clinical Perspective

Talking about blood pressure

ANTI- HYPERTENSIVE AGENTS

Systolic Blood Pressure Intervention Trial (SPRINT)

EFFICACY & SAFETY OF ORAL TRIPLE DRUG COMBINATION OF TELMISARTAN, AMLODIPINE AND HYDROCHLOROTHIAZIDE IN THE MANAGEMENT OF NON-DIABETIC HYPERTENSION

2014 HYPERTENSION GUIDELINES

Using the New Hypertension Guidelines

Update in Cardiology Pharmacologic Management of Cardiovascular Risk. Christopher C. Roe, MSN, ACNP

Hypertension Update 2009

HYPERTENSION IN EMERGENCY MEDICINE Michael Jay Bresler, M.D., FACEP

Introductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs

Objective & Outline. How the JNC Process Has Evolved. Expertise Represented on JNC 8 Panel

Hypertension targets: sorting out the confusion. Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town

What s In the New Hypertension Guidelines?

Management of High Blood Pressure in Adults

Masked Hypertension. Why Should We Care? Dr. Peter J. Lin Director Primary Care Initiatives - Canadian Heart Research Centre

Transcription:

HYPERTENSION IN THE ELDERLY A BALANCED APPROACH Barry Goldlist October 31, 2014

DISCLOSURE I have not accepted any money for myself from any pharmaceutical company in the 21 st century I have accepted money in the form of unrestricted educational grants I have had patients in whom I have regretted treating their hypertension

OBJECTIVES be able to select patients who would benefit from antihypertensive treatment be able to select appropriate treatments be able to detect side effects of treatment

Question 1:SHEP STUDY This study proved that: A. Sheep do not benefit from blood pressure control B. Systolic hypertension (SH) is inevitable in the elderly and should not be treated C. SH treatment results in severe side effects D. SH treatment reduces stroke incidence

PREHISTORIC KNOWLEDGE

PRE SHEP What we knew (mostly from Framingham study): Hypertension was common in the elderly It was mostly systolic It was strongly associated with CVS morbidity (only age had a stronger association) It was unknown if treatment would result in benefit (already known for systolic/diastolic hypertension of younger adults)

SHEP STUDY (JAMA, June 1991) What we learned: Older people can tolerate antihypertensives BP medications (chlorthalidone) are effective in lowering blood pressure Strokes were prevented 30 strokes/1000 patients over 5 years (36% relative risk reduction) Comparable to studies of diastolic hypertension in younger patients Cardiovascular morbidity was decreased (predominantly CHF)

CAVEATS Only 1% of those screened were enrolled (447,921 screened, 4736 randomized, 90% of exclusions for not meeting BP requirements). Question of generalizability. 2 nd line drug (atenolol) since discredited Only a trend to decreased total mortality and CVS mortality (EWPHE and STOP did find mortality benefit) Most patients relatively young, but no difference in subgroup analyses

Question 2: Which Antihypertensive? Which of the following statements is correct? A. All antihypertensives are equally effective in the elderly. B. The only important side effect is postural hypotension with falls. C. Heartburn is a minor side effect of some medications D. Falling is a worse disease than hypertension in frail older adults

WHICH ANTIHYPERTENSIVE? British MRC trial (BMJ February 1992) Diuretics decrease stroke and CHF in older adults but beta blockers do not Confirmed by at least two meta-analyses ALLHAT (JAMA December 2002) α-blockers not good at preventing CHF Thiazides out-performed ACE-I and CCBs Elderly specific trial in NEJM February 2003, ACE-I beat diuretics LIFE (Lancet September 2002) Losartan beats atenolol (marketing study only)

HYVET (NEJM May 2008) Patients over 80 Diuretic +/- ACE-I Improvement in real end points Was the game on for good with the rules established?

THE CONTRARY OPINIONS Community cohort studies: BP= survival Finland (BMJ 1988) Britain (BMJ 1989) USA (JAGS 2001) USA (JAGS 2007) Sweden (JAGS 2008) The quality of the studies have improved over the years (correcting for confounders), yet relationship persists

OTHER OUTCOMES Medication use and non CVS outcomes in older men (JGIM 2007) BP meds resulted in physical performance Leiden 85-Plus study (JAGS 2012) BP confers resilience to physical and cognitive decline, particularly in those with preexisting physical disability Association with falls Too many articles to list (? Initiation most hazardous)

WHY THE DISCORDANCE? When well designed studies disagree, patient selection is often the reason RCTs are the gold standard, but participants are not necessarily typical patients, and patient care provided is not always generally available Community Cohort studies include all comers but require sophisticated analysis to correct for confounders

Conclusion is that some older patients are helped by antihypertensive medications while others are harmed. The questions for the clinician are as follows: 1. Which older patients should I treat? 2. How should I treat hypertension in the elderly? 3. What should I monitor?

A MATTER OF BALANCE

WHICH OLDER PATIENTS SHOULD I TREAT? Ensure proper technique and cuff size Ensure that hypertension is sustained multiple readings separated by time (home or ambulatory monitoring can be helpful) Usually only treat if BP>160 systolic

WHICH OLDER PATIENTS SHOULD I TREAT? Which measure: gestalt Frailty index Calculated life expectancy Cognitive impairment Depends on degree and type Walking speed Related to cognition

HOW SHOULD I TREAT HYPERTENSION IN THE ELDERLY? Evidence suggests that physical activity and weight control are also effective in the elderly Pharmacological management: Beta blockers OUT since British-MRC trial Alpha blockers- OUT since ALLHAT Diuretics, ACE-I s, CCB s IN ARB s possibly only if ACE-I not tolerated

General: WHAT SHOULD I MONITOR? Falls Falls Falls BP (including at times postural) Dizziness (especially postural) Lightheadedness (syncope) Falls Falls are a worse disorder than hypertension!

Diuretics DRUG MONITORING Electrolytes, blood sugar, renal function (not efficacious if significantly impaired) ACE-I s Electrolytes, renal function CCB s Constipation, ankle swelling, heartburn

GOLDLIST APPROACH DIURETIC Standard first choice Tiny older people start at 6.25/day, usual dose is 12.5/day Can increase to 25 mg/day maximum, but if adding another medication, decrease back to 12.5 ACE INHIBITOR First choice if evidence of left ventricular dysfunction or diabetes Excellent combination with a diuretic If troublesome cough, replace with an ARB

TARGET From SHEP study, goal was under 160 (or at least 10 mm drop from baseline) After years of controversy, this target has been re-established For young old with other risk factors, some have argued for tighter control Dizziness and falls are worse than hypertension in the elderly

ROLE OF CALCIUM CHANNEL BLOCKERS Excellent in controlling blood pressures Spectrum of side effects: constipation, heartburn, ankle edema, are particularly troublesome in older patients Amlodipine is CCB of choice. Reserve diltiazem for rate control. Nifedipine has most side effects and should not be used

Question 1:SHEP STUDY This study proved that: A. Sheep do not benefit from blood pressure control B. Systolic hypertension (SH) is inevitable in the elderly and should not be treated C. SH treatment results in severe side effects D. SH treatment reduces stroke incidence

Question 2: Which Antihypertensive? Which of the following statements is correct? A. All antihypertensives are equally effective in the elderly. B. The only important side effect is postural hypotension with falls. C. Heartburn is a minor side effect of some medications D. Falling is a worse disease than hypertension in frail older adults

QUESTIONS